The SONAR study—is there a future for endothelin receptor antagonists in diabetic kidney disease?

  • Cahn A
  • Cernea S
  • Raz I
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Comment on: Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Cite

CITATION STYLE

APA

Cahn, A., Cernea, S., & Raz, I. (2019). The SONAR study—is there a future for endothelin receptor antagonists in diabetic kidney disease? Annals of Translational Medicine, 7(S8), S330–S330. https://doi.org/10.21037/atm.2019.09.117

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free